BUZZ - Summit shares fall after FDA letter questions the company's research and development capabilities
路透社2026/11/18 14:26November 18 - ** Summit Therapeutics (SMMT.O) shares fell 3% in premarket trading to $10.34
** The U.S. Food and Drug Administration (FDA) issued a letter detailing the reasons for rejecting approval of Summit's experimental lung cancer drug ivonescimab (link)
** The agency said the application was based on a study in which about 60% of subjects were from China, later revised to include North American and European Union patients
** The FDA noted that there was a 17-month gap between enrollment of the first patient in China and the first patient in North America/EU
** The FDA stated that 93% of the event data showing ivonescimab reduced cancer progression risk came from China, raising concerns about its applicability to U.S. patients
** Bernstein noted that Summit conducted four early data cut-offs, increasing the risk of poor regulatory outcomes; regional risk transparency could have been improved during the approval process
** Bernstein downgraded its rating from “market perform” to “underperform”; the price target was lowered from $11.90 to $8.30
** Due to concerns about clinical and regulatory execution, the brokerage reduced the success probability of all ongoing late-stage ivonescimab trials by 25%
** As of the close of the previous trading day, the stock had fallen about 39% year to date
(To assist non-English speakers, Reuters has automated the translation of its report into several other languages. As automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by using the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays, Deutsche Bank, and others: AI boom supports the US dollar, rally expected to continue until 2027
Barclays and Deutsche Bank believe that the artificial intelligence boom will continue to support a strong US dollar.

UniCredit reaches broad agreement with Germany on the acquisition of Commerzbank
ECB President Lagarde speaks next with the Euro under 1.1000
US Pending Home Sales in October Drop to Historic Lows as High Interest Rates Continue to Suppress Housing Demand
The U.S. Pending Home Sales Index for October fell to 63, plunging 17% year-on-year and 4.7% month-on-month, reaching the lowest level on record since 2001. As a result, sales of existing homes based on contract closings have dropped to the lowest level since 2010. The chief economist of NAR stated, "Mortgage rates seem to have peaked, and October may represent the low point for contract signings in the current real estate cycle."
